TFM
ENTA icon

TFC Financial Management’s Enanta Pharmaceuticals ENTA Stock Holding History

TFC Financial Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15 Hold
1
– – ﹤0.01% 1030
2026
Q1 		$13 Buy
+1
New +$13 ﹤0.01% 990

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TFC Financial Management's ENTA Position: Q2 2026 in Review

TFC Financial Management held its Enanta Pharmaceuticals (ENTA) position steady in Q2 2026 at 1 share worth $15. The position accounts for ﹤0.01% of the portfolio, ranked #1030.

TFC Financial Management first reported a position in ENTA in Q1 2026 and has held it in 2 quarters since. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • TFC Financial Management held 1 share of Enanta Pharmaceuticals worth $15 as of Q2 2026.
  • TFC Financial Management left its Enanta Pharmaceuticals share count unchanged in Q2 2026.
  • Enanta Pharmaceuticals made up ﹤0.01% of TFC Financial Management's portfolio in Q2 2026, its #1030 holding.
  • TFC Financial Management first reported a position in Enanta Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on TFC Financial Management's 13F filing for Q2 2026, filed 23 Jul 2026.